Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03222466
Other study ID # SMH REB #:16-376
Secondary ID
Status Completed
Phase N/A
First received July 11, 2017
Last updated October 30, 2017
Start date October 6, 2017
Est. completion date October 27, 2017

Study information

Verified date October 2017
Source St. Michael's Hospital, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Although the harms of screening for prostate cancer with the prostate-specific antigen (PSA) test outweigh the benefits, 560,000 Ontario men undergo PSA screening each year. Guideline developers, such as the Canadian Task Force on Preventive Health Care (CTFPHC), have disseminated patient educational materials (PEMs) on PSA screening widely in Ontario, yet men remain confused about screening harms and benefits. One potential contributing factor may be that PEMs are typically developed by researchers and clinicians and may not address patient barriers to change. The investigators will assess whether a PSA screening PEM that is co-created with patients provides added value over PEMs developed using the traditional approach (i.e., researchers and clinicians develop a PEM with patient involvement in usability testing only. The investigators will also assess satisfaction with the engagement process and calculate the costs and resources required for each method (i.e. co-creation, usability, and recommendations only). This study will generate a PSA screening PEM to help patients make evidence-based screening decisions. It will also help Ontario organizations, including Cancer Care Ontario, identify optimal methods for developing PEMs for PSA screening and other areas of preventive health care, such as breast and colorectal cancer screening.


Recruitment information / eligibility

Status Completed
Enrollment 573
Est. completion date October 27, 2017
Est. primary completion date October 27, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria:

- English-speaking men aged 40+ years will be eligible to take part in the project if they have never been diagnosed with prostate cancer and do not have any signs or symptoms of prostate cancer.

Exclusion Criteria:

- Individuals will not be eligible for the project if they indicate that they are a health care professional or have any conflicts of interest relevant to the guideline topic (e.g., owning shares in a company related to prostate cancer treatment).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Co-created PEM
A co-created PEM has been designed in collaboration with patients.

Locations

Country Name City State
Canada St. Michael's Hospital Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
St. Michael's Hospital, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pretest-posttest change in prostate cancer screening decisional conflict and intention to be screened between the co-created PEM group and the traditional PEM group. The investigators will assess differences and changes in prostate cancer screening decisional conflict and intention to be screened for the co-created PEM group and the traditional PEM group using repeated measures ANOVAs. This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month.
Secondary Pretest-posttest change in knowledge of prostate cancer screening The investigators will assess the differences in the pretest-posttest change in prostate cancer screening knowledge between the co-created PEM group and the traditional PEM group using a 7-item knowledge measure. Assessed by conducting a repeated measures analysis of variance (ANOVA). This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month.
Secondary Comparison of PEM usability The investigators will assess the differences between the two study arms in PEM/recommendation usability using a one-way ANOVA This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month.
Secondary Participant preference of PEM The investigators will evaluate participants' preferred material (co-created or traditional PEM). Use a chi-square test to analyze the difference in the proportion of patients who prefer each type of material. This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month
Secondary Resources use for PEM development The investigators will record the resources required (e.g., personnel hours and participant reimbursement) for a health care organization to develop a co-created PEM in comparison to a PEM created by clinicians and researchers. This measure will be assessed after the intervention (survey) is administered (i.e., post analysis), up to 1 month.